Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 5/2018

Open Access 01-05-2018 | Original Paper

Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients

Authors: Lewis J. Haddow, Rosanna Laverick, Marina Daskalopoulou, Jeffrey McDonnell, Fiona C. Lampe, Richard Gilson, Andrew Speakman, Andrea Antinori, Pietro Balestra, Tina Bruun, Jan Gerstoft, Lars Nielsen, Anna Vassilenko, Simon Collins, Alison J. Rodger, For the Cognitive Impairment in People with HIV in the European Region (CIPHER) Study Group

Published in: AIDS and Behavior | Issue 5/2018

Login to get access

Abstract

We conducted a cross-sectional study in 448 HIV positive patients attending five European outpatient clinics to determine prevalence of and factors associated with neurocognitive impairment (NCI) using computerized and pen-and-paper neuropsychological tests. NCI was defined as a normalized Z score ≤−1 in at least 2 out of 5 cognitive domains. Participants’ mean age was 45.8 years; 84% male; 87% white; 56% university educated; median CD4 count 550 cells/mm3; 89% on antiretroviral therapy. 156 (35%) participants had NCI, among whom 26 (17%; 5.8% overall) reported a decline in activities of daily living. Prevalence of NCI was lower in those always able to afford basic needs (adjusted prevalence ratio [aPR] 0.71, 95% confidence interval [CI] 0.54–0.94) or with a university education (aPR 0.72, 95% CI 0.54–0.97) and higher in those with severe depressive symptoms (aPR 1.53, 95% CI 1.09–2.14) or a significant comorbid condition (aPR 1.40, 95% CI 1.03–1.90).
Literature
1.
Bhaskaran K, Mussini C, Antinori A, et al. CASCADE collaboration. Changes in the incidence and predictors of human immunodeficiency virus associated dementia in the era of highly active antiretroviral therapy. Ann Neurol. 2008;63(2):213–21.CrossRefPubMed
2.
Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24(9):1243–50.PubMed
3.
Heaton RK, Clifford DB, Franklin DRJ, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75(23):2087–96.CrossRefPubMedPubMedCentral
4.
Bonnet F, Amieva H, Marquant F, et al. Cognitive disorders in HIV-infected patients: are they HIV-related? AIDS. 2013;27(3):391–400.CrossRefPubMed
5.
Garvey LJ, Surendrakumar V, Winston A. Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy. HIV Clin Trials. 2011;12(6):333–8.CrossRefPubMed
6.
Crum-Cianflone NF, Moore DJ, Letendre S, et al. Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. Neurology. 2013;80(4):371–9.CrossRefPubMedPubMedCentral
7.
8.
Wright EJ, Grund B, Robertson K, et al. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology. 2010;75(10):864–73.CrossRefPubMedPubMedCentral
9.
Bragança M, Palha A. Depression and neurocognitive performance in Portuguese patients infected with HIV. AIDS Behav. 2011;15(8):1879–87.CrossRefPubMed
10.
Maki PM, Rubin LH, Valcour VG, et al. Cognitive function in women with HIV: findings from the Women’s Interagency HIV Study. Neurology. 2015;84(3):231–40.CrossRefPubMedPubMedCentral
11.
Wright EJ, Grund B, Cysique LA, et al. Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT strategic timing of antiretroviral treatment (START) trial. HIV Med. 2015;16(Suppl 1):97–108.CrossRefPubMed
12.
13.
Carey CL, Woods SP, Gonzalez R, et al. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol. 2004;26(3):307–19.CrossRefPubMed
14.
Maruff P, Thomas E, Cysique LA, et al. Validity of the Cogstate brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol. 2009;24(2):165–78.CrossRefPubMed
15.
Overton ET, Kauwe JS, Paul R, et al. Performances on the Cogstate and standard neuropsychological batteries among HIV patients without dementia. AIDS Behav. 2011;15(8):1902–9.CrossRefPubMedPubMedCentral
16.
Becker JT, Dew MA, Aizenstein HJ, Lopez OL, Morrow L, Saxton J. Concurrent validity of a computer-based cognitive screening tool for use in adults with HIV disease. AIDS Pat Care STDs. 2011;25(6):351–7.CrossRef
17.
Gonzalez R, Heaton RK, Moore DJ, et al. Computerized reaction time battery versus a traditional neuropsychological battery: detecting HIV-related impairments. J Int Neuropsych Soc. 2003;9(1):64–71.CrossRef
18.
Weaver Cargin J, Maruff P, Collie A, Masters C. Mild memory impairment in healthy older adults is distinct from normal aging. Brain Cogn. 2006;60(2):146–55.CrossRefPubMed
19.
Harrison J, Maruff P. Measuring the mind: assessing cognitive change in clinical drug trials. Expert Rev Clin Pharmacol. 2008;1(4):471–3.CrossRefPubMed
20.
Lim YY, Ellis KA, Harrington K, et al. Use of the Cogstate Brief Battery in the assessment of Alzheimer’s disease related cognitive impairment in the Australian imaging, biomarkers and lifestyle (AIBL) study. J Clin Exp Neuropsychol. 2012;34(4):345–58.CrossRefPubMed
21.
Cysique LAJ, Maruff P, Darby D, Brew BJ. The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery. Arch Clin Neuropsychol. 2006;21:185–94.CrossRefPubMed
22.
Winston A, Puls R, Kerr SJ, et al. Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study. HIV Med. 2012;13(4):245–51.PubMed
23.
McDonnell J, Haddow LJ, Daskalopoulou M, et al. Minimal cognitive impairment in UK HIV positive men who have sex with men: effect of case definitions, and comparison with the general population and HIV negative men. J Acquir Immune Defic Syndr. 2014;67(2):120–7.CrossRefPubMedPubMedCentral
24.
Ashby J, Foster CJ, Garvey LJ, et al. Cerebral function in perinatally HIV-infected young adults and their HIV-uninfected sibling controls. HIV Clin Trials. 2011;16(2):81–7.CrossRef
25.
Falleti MG, Maruff P, Collie A, Darby DG. Practice effects associated with the repeated assessment of cognitive function using the Cogstate battery at 10-minute, one week and one month test-retest intervals. J Clin Exp Neuropsychol. 2006;28(7):1095–112.CrossRefPubMed
26.
Gandhi NS, Skolasky RL, Peters KB, et al. A comparison of performance-based measures of function in HIV-associated neurocognitive disorders. J Neurovirol. 2011;17:159–65.CrossRefPubMedPubMedCentral
27.
Tombaugh TN, Kozak J, Rees L. Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming. Arch Clin Neuropsychol. 1999;14(2):167–77.PubMed
28.
Ruff RM, Light RH, Parker SB, Levin HS. Benton controlled oral word association test: reliability and updated norms. Arch Clin Neuropsychol. 1996;11(4):329–38.CrossRefPubMed
29.
Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702–6.CrossRefPubMed
30.
Obermeit LC, Beltran J, Casaletto KB, et al. Evaluating the accuracy of self-report for the diagnosis of HIV-associated neurocognitive disorder (HAND): defining “symptomatic” versus “asymptomatic” HAND. J Neurovirol. 2016.
31.
Grant I, Franklin DR, Deutsch R, et al. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014;82(23):2055–62.CrossRefPubMedPubMedCentral
32.
Rourke SB, Gill J, Rachlis A, et al. Asymptomatic neurocognitive impairment (ANI) is associated with progression to symptomatic HIV-associated neurocognitive disorders (HAND) in people with HIV: results from The Ontario HIV Treatment Network (OHTN) cohort study. 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention. Vol Abstract WEPEB326. Vancouver, Canada, 2015.
33.
Ellis RJ, Badiee J, Vaida F, et al. Nadir CD4 is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS. 2011;25(14):1747–51.CrossRefPubMed
34.
McGowan JA, Sherr L, Rodger AJ, et al. Age, time living with HIV, and self-rated health among people with HIV in the UK. HIV Med. 2016.
35.
Heaton RK, Franklin DR, Deutsch R, et al. Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis. 2015;60(3):473–80.CrossRefPubMed
36.
Tozzi V, Balestra P, Serraino D, et al. Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retroviruses. 2005;21(8):706–13.CrossRefPubMed
37.
Cole MA, Margolick JB, Cox C, et al. Longitudinally preserved psychomotor performance in long-term asymptomatic HIV-infected individuals. Neurology. 2007;69(24):2213–20.CrossRefPubMed
38.
Metadata
Title
Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients
Authors
Lewis J. Haddow
Rosanna Laverick
Marina Daskalopoulou
Jeffrey McDonnell
Fiona C. Lampe
Richard Gilson
Andrew Speakman
Andrea Antinori
Pietro Balestra
Tina Bruun
Jan Gerstoft
Lars Nielsen
Anna Vassilenko
Simon Collins
Alison J. Rodger
For the Cognitive Impairment in People with HIV in the European Region (CIPHER) Study Group
Publication date
01-05-2018
Publisher
Springer US
Published in
AIDS and Behavior / Issue 5/2018
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-017-1683-z

Other articles of this Issue 5/2018

AIDS and Behavior 5/2018 Go to the issue

Original Paper

A Longitudinal Analysis of the Impact of Physical Activity on Neurocognitive Functioning Among HIV-Infected Adults

Original Paper

Depressive Symptoms, Alcohol and Drug Use, and Physical and Sexual Abuse Among Men Who Have Sex with Men in Kisumu, Kenya: The Anza Mapema Study

Original Paper

Psychopathology Subgroups and HIV Risk Among Women in Psychiatric Treatment

Original Paper

HIV Prevalence Among Hospitalized Patients at the Main Psychiatric Referral Hospital in Botswana

Brief Report

Gender Moderates the Association of Depressive Symptoms to Sexual Risk Behavior Among HIV-Positive African-American Outpatients

Original Paper

Reliability, Validity, and Factor Structure of the Hopkins Symptom Checklist-25: Population-Based Study of Persons Living with HIV in Rural Uganda
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits